Citation

Hoque R, Chesson AL. J. Clin. Sleep Med. 2009; 5(5): 471-476.

Affiliation

Sleep Disorders Center, Department of Neurology, Louisiana State University School of Medicine, Shreveport, LA, USA. romy.hoque@gmail.com

Copyright

(Copyright © 2009, American Academy of Sleep Medicine)

DOI

unavailable

PMID

19961034

PMCID

PMC2762721

Abstract

Zolpidem is a hypnotic which acts at the GABAA receptor and is indicated for short-term insomnia. Sleep related disorders including somnambulism, sleep related eating and sleep-driving have been reported with zolpidem. A 51-year-old insomniac who used zolpidem 10 mg nightly starting at 44 years of age is described. A few weeks after starting zolpidem she began walking, eating, and had one episode of driving while asleep. Episodes of sleep related eating, sleepwalking, and sleeptalking occurred 3 nights per week, 1 to 2 h after sleep onset. After her evaluation, the patient's zolpidem was gradually discontinued, and all sleep related activities immediately ceased. An 18F-FDG-PET was obtained 2 months after discontinuation of zolpidem. The following day, FDG was administered 1 h after oral administration of 10 mg zolpidem, and then a second PET was performed. We report the results and a review of the literature regarding other unintended effects seen with zolpidem use.

Language: en